IONIQ Sciences: Edison Open House Healthcare 2022

IONIQ Sciences: Edison Open House Healthcare 2022

IONIQ Sciences is at the forefront of early cancer detection. IONIQ Sciences is decoding the science of the body’s earliest response to the presence of cancer.

• How is the company using bioimpedance, an old technology, in a new way to treat cancer?
• Is the purpose to highlight whether further investigations need to take place?
• Do you require a skilled operator to carry out the test and someone else to interpret it?
• What makes your cancer detection platform different and why does it have significant advantages?
• What is the impact of not submitting the patient to ionising radiation?
• What have the key business changes been since you joined as CEO in 2018?
• Tell us about your recent research and regulatory milestones.
• Are there risks of over-diagnosis with early detection?


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.